Programmed death ligand 2 – A link between inflammation and bone loss in rheumatoid arthritis
Stinne Ravn Greisen(Aarhus University), Bent Deleuran(Aarhus University), Peter Junker(Odense University Hospital), Jesper Skovhus Thomsen(Aarhus University), Akilan Krishnamurthy(Karolinska University Hospital), Kristian Stengaard‐Pedersen(Aarhus University Hospital), Arlene H. Sharpe(Brigham and Women's Hospital), Anca I. Catrina(Karolinska University Hospital), Ellen‐Margrethe Hauge(Aarhus University), Malene Hvid(Aarhus University), Lakshmanan Annamalai(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kim Hørslev‐Petersen(University of Southern Denmark), Merete Lund Hetland(University of Copenhagen), Tue Wenzel Kragstrup(Aarhus University), Mikkel Østergaard(University of Copenhagen), Gordon J. Freeman(Dana-Farber Cancer Institute), Søren K. Moestrup(University of Southern Denmark), Lykke Midtbøll Ørnbjerg(Glostrup Hospital), Aida S. Hansen(Aarhus University)
Cited by 12
Related Papers
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
|The Journal of Experimental Medicine|2009|2k
Increased Energy Expenditure, Decreased Adiposity, and Tissue-Specific Insulin Sensitivity in Protein-Tyrosine Phosphatase 1B-Deficient Mice
|Molecular and Cellular Biology|2000|1.2k